Metabolomic signatures of five longevity interventions in male UM-HET3 mice
In male UM-HET3 mice treated from 4 to 12 months, five different longevity interventions shared some metabolic changes, notably higher ergothioneine in plasma and brain; the abstract reports no survival outcomes. [1]
Automatic summary · not editorially reviewed
The key findings
Male UM-HET3 mice received one of five longevity interventions from 4 to 12 months of age, and seven tissues were analyzed. [1]
Models trained on four interventions classified mice from a fifth, unseen intervention, which the authors interpret as shared metabolic alterations. [1]
Ergothioneine was elevated by all five interventions in plasma and brain and by four of five in muscle. [1]
The source at a glance
- Study type / format
- Preclinical multi-tissue metabolomic study in mice (abstract)
- Population / context
- Male UM-HET3 mice treated from 4 to 12 months of age
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- June 25, 2026
Five interventions tested in male mice
The abstract describes a multi-tissue metabolomic analysis of male UM-HET3 mice given one of five interventions said to be validated for longevity: rapamycin, acarbose, 17α-estradiol, canagliflozin or caloric restriction. Treatment ran from 4 to 12 months of age. Seven tissues were examined. The stated aim was to understand the metabolic mechanisms behind longevity interventions, which the authors call poorly understood.
Supporting source [1]
Shared metabolomic pattern across treatments
Using a machine-learning pipeline, the authors report that metabolic profiles could identify treated mice as likely recipients of a lifespan-extending intervention well before survival differences would appear. A leave-one-intervention-out test found that models trained on any four interventions classified mice from the fifth, unseen intervention. The authors interpret this as shared metabolic alterations across mechanistically distinct treatments. Ergothioneine, described as a dietary antioxidant, was elevated by all five interventions in plasma and brain and by four of five in muscle; other influential metabolites differed by tissue. Lipid-class remodeling was found in plasma, perigonadal fat and kidney.
Supporting source [1]
Abstract-only scope and open validation
This explainer is based on the abstract only; the full text was not reviewed. The abstract reports no survival results, so the link between these metabolic profiles and actual lifespan is not shown here. The authors themselves say the path toward metabolomic screening of candidate anti-aging drugs is pending validation against interventions that do not extend lifespan. These are findings in male mice, not evidence of benefit for people.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No survival outcomes are reported, so links to lifespan are not shown. The authors state validation against interventions that do not extend lifespan is still pending. Findings are in male mice.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Badenoch B, Fiehn O, Rappaport N, Greenfield S, Chandrasekaran S, Miller RA. · europepmc.org · June 25, 2026